Scientists test supercharged immune cells against stubborn blood cancer
Disease control
Ongoing
This early-stage study is testing a new combination treatment for multiple myeloma that has come back or stopped responding to other therapies. It combines a lab-modified version of a patient's own immune cells (called TiNK cells) with a drug called isatuximab, along with standar…
Phase: PHASE1 • Sponsor: Elvira Umyarova • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC